Novo Nordisk built modern obesity pharmacology. Liraglutide came first in 2009, with Saxenda following in 2014. Semaglutide split into three products — Ozempic for type-2 diabetes, Wegovy for obesity, and Rybelsus as the oral form. The 2025 and 2026 cadence has been about defending that position against Lilly's tirzepatide while moving the next generation forward.
The May 6 Q1 2026 print landed strong: net sales DKK 96.82B (+24% YoY), operating profit DKK 59.62B (+54%). Wegovy pill drove the upside with DKK 2.26B (~$354M) in Q1 — almost 2× analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative since the January 5 launch. CEO Mike Doustdar told CNBC on May 6 that Wegovy holds 65% of all new US GLP-1 prescriptions, calling the moment a 'turnaround situation.' NovoCare priced the 1.5 mg starter at $149/month and moved the 4 mg dose from $149 to $199 effective April 15. On May 1, Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill at 1.5/4/9 mg with improved-absorption reformulation across 70,000+ pharmacies. Wegovy HD 7.2 mg launched April 7 with a STEP UP 21% mean weight loss anchor. Full-year guidance tightened to a 4–12% sales-and-operating-profit decline (from the prior 5–13%) — Jefferies pushed back that the lower-end guidance was not lifted enough to be a positive surprise.
The pipeline gets harder from here. CagriSema (cagrilintide + semaglutide) failed to match Zepbound in February's head-to-head readout (23% vs 25.5%), and the Q1 documents disclosed Novo has discontinued the single-chamber co-formulation device — the dual-chamber injectable system continues with the original FDA filing already submitted and a higher-dose Phase 3 trial slated for H2 2026. Petrelintide and amycretin-prodrug sit further back. The Indian semaglutide patent expired in March 2026 and licensed generics from Biocon and Dr. Reddy's followed within weeks.
International milestones continued through Q2 2026. Japan's MHLW granted Novo Nordisk a partial change approval on June 19, 2026 making Wegovy the first approved MASH treatment in Japan (without cirrhosis, moderate-to-advanced fibrosis), co-promoted with Sumitomo Pharma under the October 2025 co-promotion agreement and based on ESSENCE Phase 3 Part 1 data. France joined the UK and Switzerland with public-insurance reimbursement effective June 15, 2026 at 65% Sécurité Sociale coverage, and the UAE became the first ex-US Wegovy pill launch on June 3.
September 7, 2026 was a split-decision day. STEP Young reported that 40.4% of children aged 6 to under 12 with obesity achieved a BMI below the obesity threshold at week 68 on semaglutide plus lifestyle modification, versus 0% on placebo, with safety consistent with adult and adolescent trials and no signal on growth or pubertal development — potentially opening a supplemental filing path to extend Wegovy below its current 12-and-older label. On the same day the company confirmed it had terminated the HERMES and ATHENA Phase 3 heart failure trials of ziltivekimab (anti-IL-6 monoclonal antibody) early after a data monitoring committee ruled the studies unlikely to succeed, following the June 2026 ZEUS miss. A post-acute heart-failure study of ziltivekimab remains ongoing, but the non-GLP-1 diversification story has narrowed further.
Analyst sentiment split further into the week of September 8-11. HSBC raised its Novo Nordisk target to DKK 320 from DKK 300 (Hold, September 9) after early-week positive newsflow, and Barclays cut its target from DKK 310 to DKK 300 (Equal Weight, September 8) after the STEP Young + ziltivekimab split announcement. Morgan Stanley's Thibault Boutherin then downgraded Novo to Underweight from Equal-weight on Friday September 11, cutting the price target to DKK 250 (implying more than 10% downside) on concerns that current valuation does not reflect the subdued mid-term growth outlook or the semaglutide patent-cliff impact on Novo's terminal value. Morgan Stanley flagged that semaglutide is expected to account for approximately 75% of 2026 sales, with loss of exclusivity beginning in 2031, and cited weaker U.S. Wegovy pill script momentum after a stronger first half. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. The company continued executing the DKK 15 billion share repurchase programme (DKK 9.02 billion completed through September 4).
On Monday September 14, 2026 the company said it would use 'Novo' as its day-to-day name, while Novo Nordisk A/S remains its legal name. The rebrand introduced the platform 'Lasting Health Starts Now,' an updated version of the Apis bull logo, and a culture framework called The Novo Way, and the company said it would give more detail on its strategy at a Capital Markets Day in London on September 21. On Wednesday September 16, Novo and Anthropic announced a collaboration under which Novo will test Anthropic's Claude Science in research and development workflows; financial terms were not disclosed. On Thursday September 17, Novo signed a multi-target discovery and license agreement with Orbis Medicines, a Copenhagen and Lausanne company that designs oral macrocycle drugs, worth up to $1.4 billion in upfront and milestone payments plus tiered royalties, along with a strategic investment of undisclosed size. Orbis's chief executive said its macrocycles have reached up to 18% oral bioavailability in preclinical studies.
Novo set out its 2030 ambitions at the Capital Markets Day in London on Monday September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and grow revenue from 2026 to 2030 in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035 and said the ambitions are not financial guidance. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned in oral and injectable forms. Shares fell as much as 9% during the day, BNN Bloomberg reported, as management faced questions on pricing and dealmaking.
Novo Nordisk announced on June 11 that the UK Medicines and Healthcare products Regulatory Agency had approved the Wegovy pill (oral semaglutide tablets 25 mg) for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, making the UK the third national authority to license the molecule after the FDA and the UAE's EDE. The approval rests on the Phase 3 OASIS 4 trial, which showed about 13.6% weight loss with the 25 mg tablet versus 2% on placebo. Private-prescription availability is expected within weeks; NHS coverage requires a separate NICE cost-effectiveness appraisal.
Novo Nordisk launched the Wegovy pill in the United Arab Emirates on June 3, the first country outside the US to make the oral semaglutide tablet available since the January 5 US launch. The UAE rollout used a distribution structure that piggybacks on existing diabetes-channel infrastructure rather than a parallel direct-to-consumer build, and arrived ahead of the UK MHRA approval today. Novo had previously guided to second-half 2026 for international rollouts.
A June 7 Novo Nordisk announcement, timed to ADA 2026, said the Wegovy pill (oral semaglutide 25 mg) had surpassed 3 million US prescriptions since its January 5 launch, with one prescription filled roughly every five seconds. The first million took 12 weeks (to March 23); the next 2 million came in 10 weeks. More than 80% of new Wegovy pill scripts go to patients new to GLP-1 therapy, suggesting market expansion rather than brand switching, and the first international launches outside the US are set for the second half of 2026.
BioPharma Dive's June 8 ADA wrap framed the meeting's competitive sort: Lilly reinforced its lead with retatrutide (28.3%) and Foundayo's head-to-head win over oral semaglutide; Pfizer's berobenatide emerged as 'foundational' with the monthly-dosing differentiation; Roche's enicepatide drew 'me-too' framing from RBC's Trung Huynh ('does little to differentiate enicepatide from its peers'). Novo Nordisk lost ground after CagriSema missed non-inferiority versus its target competitor on some endpoints. Lilly closed about 4.5% higher Monday on the data; Novo fell 3.46%.
Novo Nordisk closed 3.46% lower Monday June 8 as investor attention focused on Lilly's clear ADA win and on CagriSema's failure to demonstrate non-inferiority against a competitor on some obesity endpoints. CVS Caremark's earlier formulary tilt toward Lilly's Zepbound (announced in late May, effective October 1) and the broader oral GLP-1 picture compound the pressure. Novo's Wegovy pill remains the only US-approved oral, but the next-wave pipeline narrative now skews to Lilly.
Novo Nordisk presented the full REIMAGINE 1/2/3 Phase 3 program in a Sunday symposium at ADA 2026, with simultaneous publication in The Lancet Diabetes & Endocrinology (REIMAGINE 1 and 2) and The Lancet (REIMAGINE 3). REIMAGINE 2 (n=2,713; 68 weeks) showed CagriSema 2.4/2.4 mg producing 14.2% weight loss and 1.91% HbA1c reduction versus 10.2% and 1.75% for semaglutide 2.4 mg alone. REIMAGINE 1 (n=189; 40 weeks) showed 13.8% weight loss and 1.8% HbA1c drop vs placebo. REIMAGINE 3 (n=274) showed 12.0% weight loss and a 2.33% HbA1c drop when added to basal insulin.
Novo Nordisk presented Phase 2 data for zenagamtide (formerly amycretin), its unimolecular GLP-1 and amylin receptor agonist, at ADA 2026 in 262 adults with type 2 diabetes randomized across six subcutaneous doses (0.4 to 40 mg) versus placebo. The 40 mg arm cut HbA1c by 1.71 percentage points and reduced body weight by 14.6% at 36 weeks, with nearly 89% of patients reaching HbA1c below 7%. The study met its primary HbA1c endpoint across all doses; Novo plans Phase 3 in H2 2026 and hosted a same-day R&D investor event.
Novo Nordisk hosted its R&D investor event in New Orleans on Sunday June 7, the same day as the CagriSema and zenagamtide readouts. The pipeline conversation centered on the combination strategy that pairs CagriSema and zenagamtide with the Wegovy injection and Wegovy pill, plus IcoSema and the FGF21 analog efruxifermin in MASH. Across 40 ADA abstracts, the company is reframing itself from a single-product GLP-1 leader to a multi-mechanism cardiometabolic pipeline.
At ADA 2026, Novo Nordisk reported full Phase 3 REIMAGINE 2 data for CagriSema (cagrilintide plus semaglutide fixed-dose combination) in 2,728 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Over 68 weeks, CagriSema 2.4 mg/2.4 mg produced superior HbA1c reduction of 1.91 percentage points and 14.2% mean weight loss, both better than the semaglutide 2.4 mg, cagrilintide 2.4 mg, and placebo comparator arms. The readout is the first head-to-head Phase 3 win for the dual amylin/GLP-1 combination over its individual components.
Ahead of the ADA Scientific Sessions (June 5-8, New Orleans), Novo Nordisk previewed 40 abstracts spanning pivotal Phase 3 CagriSema in the REIMAGINE type 2 diabetes program, new mid-stage data for the amylin/GLP-1 agonist zenagamtide (the molecule previously called amycretin), and IcoSema and semaglutide analyses. Novo said its obesity and diabetes products reached 45.3 million patients by March 2026, with obesity up 58% year over year, and will host an R&D investor event June 7.
Novo Nordisk extended its EASL 2026 ESSENCE presentation cycle into Day 2 with real-world evidence quantifying the MASH disease burden — documenting significant quality-of-life impairment and escalating healthcare costs in MASH patients — alongside the Japanese MASH and menopausal women subgroup analyses presented Day 1. The data builds the health-economic case for semaglutide 2.4 mg following the August 2025 FDA MASH-with-fibrosis approval. MASH affects roughly 1 in 3 people living with overweight or obesity worldwide, with the majority undiagnosed. Novo's 'Love Your Liver' EASL initiative offered on-site MASH testing for attendees. The real-world burden data complements the ESSENCE Phase 3 efficacy story by establishing the economic and quality-of-life rationale for early MASH intervention — a payer-facing argument as the GLP-1 MASH indication scales into 2026-2027 against the THR-β, FGF21, and GLP-1/glucagon competitor classes.
Novo Nordisk presented two ESSENCE Phase 3 subgroup analyses at EASL 2026 today. The Japanese MASH subgroup analysis extends the semaglutide 2.4 mg efficacy and safety case to Asian populations where MASLD and MASH develop at lower body-mass-index thresholds and involve distinct metabolic risk profiles. The Menopause subgroup analysis covers women in menopause, where hormonal changes accelerate liver disease progression and metabolic deterioration. Both analyses show consistent hepatic safety profile and efficacy across the underrepresented groups. The August 2025 FDA MASH-with-fibrosis approval of semaglutide 2.4 mg was based on the broader ESSENCE Phase 3 cohort; the EASL Day 1 presentations strengthen the global labeling case across non-Western populations and the menopausal-women subgroup that has historically been underrepresented in MASH clinical trials. Real-world evidence data presented today documents quality-of-life impairment and healthcare-cost escalation in MASH patients.
Novo Nordisk announced May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy 7.2 mg in a single-dose pen for adults living with obesity. Wegovy 7.2 mg is the high-dose once-weekly injectable formulation already available in the US as Wegovy HD. The STEP UP Phase 3 trial demonstrated 20.7% mean weight loss with the 7.2 mg dose, with approximately one in three participants experiencing ≥25% weight loss; in the STEP UP T2D trial, the same dose produced 14.1% mean weight loss in adults with obesity and type 2 diabetes. Novo expects to launch Wegovy 7.2 mg in the EU in Q3 2026. The CHMP opinion arrived the same day as the parallel positive recommendation for Wegovy pill (oral semaglutide 25 mg) — completing Novo's twin EU regulatory wins for the higher-dose injectable and the oral formulation simultaneously.
Cumulative US Wegovy pill prescriptions, as disclosed in Novo Nordisk CEO Maziar Doustdar's May 14 commentary (>1M) and EVP Larsen's May 18 commentary on CNBC (>2M), continued to trend upward through the Memorial-Day-week lead-in. Weekly Wegovy pill volume of approximately 142,000 for the week ending May 15 — slightly above the prior week's 137,000 after the brief mid-May decline — suggests cumulative US prescriptions are now in the 2.1-2.15M range. The Wegovy pill launch (January 5, 2026) trajectory continues to outpace the comparable Wegovy injectable launch (June 2021), positioning Novo for the projected H2 2026 EU launches in UK, Germany, and Denmark. The Wegovy HD (7.2 mg injectable) CHMP positive opinion announced May 22 adds the high-dose franchise to the EU portfolio.
Novo Nordisk announced on May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain long-term weight reduction. The recommendation includes data from SELECT in the label — the cardiovascular outcomes trial that documented a 20% major adverse cardiovascular event reduction with injectable Wegovy. The CHMP opinion is the first oral GLP-1 EU approval recommendation for weight management. OASIS 4 Phase 3 data anchoring the filing: 16.6% mean weight loss in adults with obesity or overweight plus one comorbidity, comparable to injectable Wegovy 2.4 mg. Novo plans to launch the pill in select non-US markets in H2 2026, with UK, Germany, and Denmark previously flagged as the first international launches (CNBC May 18). The CHMP opinion confirms the international expansion path Novo's EVP Larsen described.
Industry commentary May 22 framed Novo Nordisk's strategic response to retatrutide's TRIUMPH-1 readout as a two-track amylin strategy. CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) is the near-term play — Phase 3 REDEFINE-1 and REDEFINE-2 complete, FDA filing under review with decision expected late 2026, and Novo positioning the safety profile as the competitive edge after REDEFINE-4 missed non-inferiority versus tirzepatide 15 mg in February 2026. Amycretin (dual GLP-1/amylin agonist) is the long-term bet — AMAZE-12 Phase 3 began recruiting May 18 testing the dual agonist for weight maintenance, with Phase 1 results showing 22% weight loss at 36 weeks weekly subcutaneous and 13.1% at 12 weeks oral. The CagriSema higher-dose Phase 3 starts H2 2026; REDEFINE-11 reads out H1 2027. Combined, the amylin axis is structurally Novo's most direct response to Lilly's triple-agonist mechanism — adding amylin tone (slower gastric emptying, satiety persistence, weight-maintenance) rather than competing on glucagon-driven energy expenditure.
A May 21 Research and Markets report projected the global GLP-1 receptor agonist weight loss drug market expanding from $15.5B in 2025 to $18.02B in 2026 — a 16.3% compound annual growth rate. The forecast tracks through 2030 and 2035 across major players Novo Nordisk, Eli Lilly, and Pfizer, plus the growing oral GLP-1 segment (Wegovy pill, Foundayo, Structure Therapeutics' aleniglipron entering Phase 3). By 2020 roughly 4 million people were on GLP-1s; by 2026 that estimate has reached 30 million. The market data is the formal backdrop for the broader 2026 obesity-pharmacology conversation: GLP-1 alone is now larger than the 2024 oncology drug class's largest single product. The IQVIA peptide-CDMO capacity-build wave (Bachem, PolyPeptide, CordenPharma SPPS expansions through 2028) and the Lilly $4.5B Lebanon Indiana investment lean directly into the demand projection.
Novo Nordisk's AMAZE-12 Phase 3 trial of amycretin — a dual GLP-1 and amylin receptor agonist — began recruiting on May 18, 2026. The trial evaluates amycretin specifically for weight maintenance after initial weight loss, distinguishing it from AMAZE-1 (which measures body weight change over 84 weeks). The amycretin clinical rationale rests on Phase 1 weekly subcutaneous dosing producing 22% weight reduction at 36 weeks and oral formulation producing 13.1% at 12 weeks — both reported in the Lancet earlier in 2026. Amycretin sits within Novo's next-generation pipeline alongside CagriSema (cagrilintide + semaglutide, FDA filing under review with decision expected late 2026) and the orexin-related pipeline acquired via Centessa. The amycretin program is structurally Novo's most direct response to Lilly's retatrutide.